VX-01

Vantage Biosciences Ltd · Phase 2 active Small molecule

At a glance

Generic name	VX-01
Sponsor	Vantage Biosciences Ltd
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01 (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VX-01 CI brief — competitive landscape report
VX-01 updates RSS · CI watch RSS
Vantage Biosciences Ltd portfolio CI